The mitogen actived protein kinases (MAPK) pathway, a target for anticancer drugs;La voie des mitogen actived protein kinases (MAPK), cible de stratégies antitumorales

Bulletin du Cancer

Volumn 93, Issue SPEC. ISS. APR., 2006, Pages 25-30

  Favre, Gilles ^a  

^a CNRS   (France)

Author keywords

Erk; Mek; Mitogen activated protein kinase; Raf; Ras

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CYCLINE; DNA POLYMERASE; FARNESYL TRANS TRANSFERASE; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; RAF PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ARTICLE; CELL ACTIVATION; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; DNA REPLICATION; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE;

EID: 33745440293     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Roux P, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-44.
2. Ory S, Morrison DK. Signal transduction: implications for Ras-dependent ERK signaling. Curr Biol 2004; 14: R277-8.
3. Mazieres J, Pradines A, Favre G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett 2004; 206: 159-67.
4. Sebti SM, Der CJ. Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003; 3: 945-51.
5. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5: 875-85.
6. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23: 6771-90.
7. Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy, Curr Top Med Chem 2005; 5: 215-29.